Shreis Scalene’s Cytotron Receives the US FDA’s Breakthrough Device Designation for the Treatment of Multiple Cancer Indications

 Shreis Scalene’s Cytotron Receives the US FDA’s Breakthrough Device Designation for the Treatment of Multiple Cancer Indications

Shreis Scalene’s Cytotron Receives the US FDA’s Breakthrough Device Designation for the Treatment of Multiple Cancer Indications

Shots:

  • The US FDA’s Center for Devices and Radiological Health has granted breakthrough device designation for Shreis’ Cytotron, invented by Dr. Rajah Vijay Kumar in Bengaluru, India, indicated for the treatment of solid tumors of the breast, liver, and pancreas
  • Shreis is actively collaborating with other companies for the clinical studies of Cytotron in the proposed indications and plans to submit a request for BT designation in adult and pediatric brain tumors, lung cancer, and other life-limiting diseases
  •  The Cytotron is intended to cause degeneration of uncontrolled growth of tissues, act by selectively targeting and enabling tissue apoptosis, thus indicated to treat protein linked regenerating disorders like a neoplastic disease

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Your story

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post